Medexus Pharmaceuticals (MEDXF) Stock Price, News & Analysis

Company Overview

Medexus Pharmaceuticals, Inc. is a specialty pharmaceutical company headquartered in Mississauga, Ontario. The company focuses on acquiring, developing and commercializing niche prescription drug products for markets in Canada and the United States. Its efforts are aimed at underserved therapeutic areas, including rare diseases, oncology, hematology and dermatology.

Through strategic licensing and partnership agreements with international pharmaceutical firms, Medexus sources late‐stage and marketed assets, then manages their regulatory approval and commercialization. The company’s portfolio includes treatments for disorders such as immune thrombocytopenia, neutropenia and other hematologic conditions, as well as therapies for certain solid tumors and skin diseases. Its business model emphasizes efficient product launches and market penetration by leveraging established distribution channels and clinical expertise.

Founded in 2015, Medexus has built a commercially focused infrastructure encompassing regulatory affairs, medical affairs, sales and marketing, and market access. While primarily serving Canadian patients and healthcare providers, the company has selectively expanded into the U.S. specialty market via targeted launch strategies. Medexus’ leadership team draws on decades of experience in pharmaceutical development and commercialization to guide its growth trajectory.

Key Stats

• Today's Range: $2.77 to $2.86
• 50-Day Range: $2.15 to $2.97
• 52-Week Range: $1.80 to $3.04
• Volume: 24,811 shs
• Average Volume: 11,679 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:MEDXF
• CIK: N/A
• Web: www.medexus.com
• Phone: (514) 344-8765
• Fax: N/A
• Employees: 98
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A